Annals of Surgical Oncology

, Volume 11, Supplement 3, pp 192S–197S | Cite as

Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience

Article
Received:
Accepted:
  • 49 Downloads

Abstract

Lymph node status is the most reliable prognostic indicator for patients with melanoma and breast cancer. Because it is the first node draining the primary cancer, the sentinel lymph node (SLN) is most likely to harbor metastatic cancer cells. The Breslow thickness of the primary melanoma and the size of primary breast cancer are highly correlated with SLN metastasis. If the SLN is negative, its negative predictive value for the remaining nodal basin exceeds 95%; thus, survival rates for melanoma and breast cancer increase when the SLN is negative. The rate of SLN identification is more than 95%, and the false-negative rate is about 5%. SLN data from melanoma and breast cancer are so convincing that they have been incorporated into the new American Joint Committee on Cancer classification of these cancers. The therapeutic value of additional lymph node dissection after a positive SLN for melanoma or breast cancer is still controversial. In melanoma, a 3-year follow-up may confirm better survival when the SLN is negative. However, about 25% of histologically negative SLNs may be upstaged by molecular techniques, and patients whose SLNs are positive by polymerase chain reaction (PCR) assay may develop recurrence. In most cases, melanoma and breast cancer follow an orderly progression of metastasis to the SLN; however, a small subgroup may develop systemic dissemination without SLN involvement. Current SLN experience has confirmed that the earlier the cancer, the less its potential for metastasis. Since treatments for metastatic cancer are still limited, early detection and resection are imperative. Better understanding of the molecular and genetic mechanisms of metastasis will be critical to select high-risk patients for adjuvant therapy.

Key Words

Breast cancer Melanoma Metastasis Sentinel nodes 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma.Ann Surg 1997; 225:1–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Zettersten E, Shaikh L, Ramirez R, Kashani-Sabet M. Prognostic factors in primary cutaneous melanoma.Surg Clin North Am 2003;83:61–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Clark WH, Elder DE, DuPont G, et al. Model predicting survival in stage I melanoma based on tumor progression.J Natl Cancer Inst 1989;81:1893–904.PubMedGoogle Scholar
  4. 4.
    Liu V, Mihm MC. Pathology of malignant melanoma.Surg Clin North Am 2003;83:31–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Balch CM, Ac B, Soong S, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol 2001;19:3535–648.Google Scholar
  6. 6.
    Niederhuber JE. Seeking calmer waters in a sea of controversy.Oncologist 2002;7:172–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Von Eschenbach AC. NCI remains committed to current mammography guidelines.Oncologist 2002;7:170–1.CrossRefGoogle Scholar
  8. 8.
    Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening.Arch Surg 1996;131:301–8.PubMedGoogle Scholar
  9. 9.
    Andersen LD, Remington P, Trentham-Dietz A, Reeves M. Assessing a decade of progress in cancer control.Oncologist 2002; 7:200–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Begg CB. The mammography controversy.Oncologist 2002;7:174–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons.Cancer 1980;45:2917–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up.Radiol Clin North Am 2000;38:625–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Ibarra JA. The pathologist in breast cancer: contemporary issues in the interdisciplinary approach.Surg Oncol Clin N Am 2000;9:295–317.PubMedGoogle Scholar
  14. 14.
    Chung MA, Cady B. New lessons from the sentinel node.Surg Oncol Clin N Am 2001;10:461–73, xi–xii.PubMedGoogle Scholar
  15. 15.
    Halsted WS. The results of operations for the cure of cancer of the breast performed at The John Hopkins Hospital from June, 1889 to January, 1894. In:Operations for Cure of Cancer of the Breast. Vol. 4. Baltimore: The Johns Hopkins Press, 1894–95:497–553.Google Scholar
  16. 16.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.N Engl J Med 1985;312:674–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment.Breast Cancer Res Treat 1985; 5:17–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Reintgen DS, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases.Ann Surg 1994;220:759–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Adjuvant therapy for breast cancer.NIH Consens Statement 2000; 17:1–35.Google Scholar
  20. 20.
    Seaman W, Powers W. Studies on the distribution of radioactive colloidal gold in regional lymph nodes containing cancer.Cancer 1955;8:1044–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Gould EA, Winship T, Pholbin PH, Hyland Kerr H. Observations on a “sentinel node” in cancer of the parotid.Cancer 1960;13:77–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Cabanas RM. An approach for the treatment of penile carcinoma.Cancer 1977;39:456–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model.Ann Surg 1991;214:637–41.PubMedGoogle Scholar
  24. 24.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Surg 1992;127:392–9.PubMedGoogle Scholar
  25. 25.
    Leong SPL. Selective sentinel lymphadenectomy for malignant melanoma.Surg Clin North Am 2003;83:157–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Leong SPL, Wong JH.Sentinel Lymph Nodes in Human Solid Cancer. Vol. 80, Philadelphia: WB Saunders, 2000.Google Scholar
  27. 27.
    Borgstein P, Meijer S. Historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept.Eur J Surg Oncol 1998;24:85–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial.Ann Surg 1999;230:453–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.JAMA 1996;276:1818–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes.Melanoma Res 1995;5:255–60.PubMedGoogle Scholar
  31. 31.
    Cody HS 3rd. Sentinel lymph node mapping in breast cancer.Oncology 1999;13:25–34.PubMedGoogle Scholar
  32. 32.
    Coit D, Wallack M, Balch C. Society of Surgical Oncology practice guidelines: melanoma surgical practice guidelines.Oncology 1997;11:1317–23.PubMedGoogle Scholar
  33. 33.
    Emilia JCD, Lawrence W. Sentinel lymph node biopsy in malignant melanoma: the standard of care?J Surg Oncol 1997;65:153–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Houghton A, Coit D, Bloomer W, et al. NCCN melanoma practice guidelines. National Comprehensive Cancer Network.Oncology 1998;12:153–77.PubMedGoogle Scholar
  35. 35.
    Reintgen DS. Changing standards of surgical care for the melanoma patient.Ann Surg Oncol 1996;3:327–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Carpenter R. Sentinel node biopsy should be introduced into routine practice before results of randomized trials are available.Breast 2001;10:281–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Cherpelis BS, Haddad F, Messina J, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.J Am Acad Dermatol 2001; 44:762–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Gershenwald JE, Thompson W, Manifield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.J Clin Oncol 1999;17:976–83.PubMedGoogle Scholar
  39. 39.
    Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.Cancer 2001;91:2401–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Clary BM, Mann B, Brady MS, et al. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection.Ann Surg Oncol 2001;8:328–37.PubMedCrossRefGoogle Scholar
  41. 41.
    Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadetectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma.Ann Surg Oncol 1999;6:442–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes.Arch Surg 1999;134:381–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma.Cancer 2001;91:2110–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Starz H, De Donno A, Balda BR. The Augsburg experience: histological aspects and patient outcomes.Ann Surg Oncol 2001; 8(9 Suppl):48S-51S.PubMedGoogle Scholar
  45. 45.
    Morton D, Essner R, Hoon DS, et al.Long-Term Results of Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: Implications of Nodal Microanatomy and Molecular Staging on Detection of Nodal Micrometastasis. American Surgical Association 123rd Annual Meeting. Washington, DC: American Surgical Association, 2003:60.Google Scholar
  46. 46.
    Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer.Ann Surg 1971;173:44–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Rosen PP, Saigo PE, Braun DW, et al. Axillary micro-and macrometastases in breast cancer: prognostic significance of tumor size.Ann Surg 1981;194:585–91.PubMedGoogle Scholar
  48. 48.
    Rosen PP, Saigo PE, Braun DW, et al. Prognosis in stage II (T1N1M0) breast cancer.Ann Surg 1981;194:576–84.PubMedCrossRefGoogle Scholar
  49. 49.
    Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinomas.Cancer 1993;71:1780–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators.Cancer 1995;75:1310–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Byrne J, Horgan PG, England S, et al. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma.Eur J Cancer 1992;28:658–60.PubMedCrossRefGoogle Scholar
  52. 52.
    Chen ZL, Wen DR, Coulson WF, et al. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology.Dis Markers 1991;9:239–48.PubMedGoogle Scholar
  53. 53.
    Cote R, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph node metastases in management of breast cancer. International Breast Cancer Study Group.Lancet 1999; 354:896–900.PubMedCrossRefGoogle Scholar
  54. 54.
    Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin-positive breast cancer metastases.Mod Pathol 1989;2:516–20.PubMedGoogle Scholar
  55. 55.
    Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance.Br J Cancer 1987;55:303–6.PubMedGoogle Scholar
  56. 56.
    Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of nodenegative breast cancer patients receiving no adjuvant therapy.J Clin Oncol 2001;19:1468–75.PubMedGoogle Scholar
  57. 57.
    Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy.Ann Surg 1995; 222:394–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Wang X, Heller R, Van Voorheis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.Ann Surg 1994;220:768–74.PubMedCrossRefGoogle Scholar
  59. 59.
    Bostick P, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.J Clin Oncol 1999;17:3238–44.PubMedGoogle Scholar
  60. 60.
    Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.Ann Surg 2003;238:538–49.PubMedGoogle Scholar
  61. 61.
    Davis EG, Chao C, McMasters KM. Polymerase chain reaction in the staging of solid tumors.Cancer J 2002;8:135–43.PubMedCrossRefGoogle Scholar
  62. 62.
    McMasters K, Reintgen D, Ross M, et al. Sunbelt Melanoma Trials: sensitivity and specificity of reverse transcriptase polymerase chain reaction (RT-PCR) markers for sentinel lymph nodes (SLN).Proc Am Soc Clin Oncol 1999;18:537a.Google Scholar
  63. 63.
    Cox CE, Salud CJ, Harrinton MA. The role of selective sentinel lymph node dissection in breast cancer.Surg Clin North Am 2000;80:1759–77.PubMedCrossRefGoogle Scholar
  64. 64.
    Chen M, Palleschi S, Khoynezhad A, et al. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis.Arch Surg 2002;137:606–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer.J Clin Oncol 1997;15:2345–50.PubMedGoogle Scholar
  66. 66.
    Greene FL, Page DL, Fleming ID, et al., eds.AJCC Cancer Staging Manual. 6th ed. New York: Springer, 2003.Google Scholar
  67. 67.
    Harris JR, Henderson CI. Natural history and staging of breast cancer. In: Harris JR, Henderson CI, Hellman S, Kinne DW, eds.Breast Diseases. Philadelphia. Lippincott, 1987:233–58.Google Scholar
  68. 68.
    Leong SPL. Future perspectives on malignant melanoma.Surg Clin North Am 2003;83:453–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2004

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of CaliforniaSan Francisco
  2. 2.UCSF Comprehensive Cancer CenterSan Francisco
  3. 3.UCSF Medical Center at Mount ZionSan Francisco

Personalised recommendations